Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Study protocol

Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000

Authors: Andrew Robert Ness, Andrea Waylen, Katrina Hurley, Mona Jeffreys, Chris Penfold, Miranda Pring, Sam Leary, Christine Allmark, Stu Toms, Susan Ring, Tim J Peters, Will Hollingworth, Helen Worthington, Chris Nutting, Sheila Fisher, Simon N Rogers, Steven J Thomas, The Head and Neck 5000 Study Team

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Head and neck cancer is an important cause of ill health. Survival appears to be improving but the reasons for this are unclear. They could include evolving aetiology, modifications in care, improvements in treatment or changes in lifestyle behaviour. Observational studies are required to explore survival trends and identify outcome predictors.

Methods

We are identifying people with a new diagnosis of head and neck cancer. We obtain consent that includes agreement to collect longitudinal data, store samples and record linkage. Prior to treatment we give participants three questionnaires on health and lifestyle, quality of life and sexual history. We collect blood and saliva samples, complete a clinical data capture form and request a formalin fixed tissue sample. At four and twelve months we complete further data capture forms and send participants further quality of life questionnaires.

Discussion

This large clinical cohort of people with head and neck cancer brings together clinical data, patient-reported outcomes and biological samples in a single co-ordinated resource for translational and prognostic research.
Literature
1.
Mehanna H, Paleri V, West CML, Nutting C: Head and neck cancer-part 1: epidemiology, presentation, and prevention. Brit Med J. 2010, 341: c4684-10.1136/bmj.c4684.CrossRefPubMed
2.
Mehanna H, West CML, Nutting C, Paleri V: Head and neck cancer-part 2: treatment and prognostic factors. Brit Med J. 2010, 341: c4690-10.1136/bmj.c4690.CrossRefPubMed
3.
Drugan C, Leary S, Mellor T, Bain C, Verne J, Ness A, Thomas S: Head and neck cancer in the south west of England, Hampshire, and the Isle of Wight: trends in survival 1996–2008. Brit J Oral Max Surg. 2013, 51 (1): 19-24. 10.1016/j.bjoms.2012.02.013.CrossRef
4.
Goulart BHL, Ramsey SD, Parvathaneni U: Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. Int J Radiat Oncol. 2014, 88 (1): 106-114. 10.1016/j.ijrobp.2013.05.050.CrossRef
5.
Hemingway H, Riley RD, Altman DG: Ten steps towards improving prognosis research. Brit Med J. 2009, 339: b4184-10.1136/bmj.b4184.CrossRefPubMed
6.
Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KGM, Steyerberg EW, Roberts I, Schroter S, Altman DG, Riley RD, PROGRESS Group: Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. Brit Med J. 2013, 346: e5595-10.1136/bmj.e5595.CrossRefPubMedPubMedCentral
7.
Hughes C, Homer J, Bradley P, Nutting C, Ness A, Persson M, Jeffreys M, Waylen A, Leary S, Thomas S: An evaluation of current services available for people diagnosed with head and neck cancer in the UK (2009–2010). Clin Oncol-Uk. 2012, 24 (10): E187-E192. 10.1016/j.clon.2012.07.005.CrossRef
8.
9.
10.
Deschler D, Day T: TNM Staging of Head and Neck Cancer/Neck dissection classification. 2008, Alexandria (VA): American Academy of Head and Neck Surgery
11.
12.
Lagiou P, Georgila C, Minaki P, Ahrens W, Pohlabeln H, Benhamou S, Bouchardy C, Slamova A, Schejbalova M, Merletti F, Richiardi L, Kjaerheim K, Agudo A, Castellsague X, Macfarlane TV, Macfarlane GJ, Talamini R, Barzan L, Canova C, Simonato L, Lowry R, Conway DI, McKinney PA, Znaor A, McCartan BE, Healy C, Nelis M, Metspalu A, Marron M, Hashibe M, Brennan PJ: Alcohol-related cancers and genetic susceptibility in Europe: the ARCAGE project: study samples and data collection. Eur J Cancer Prev. 2009, 18 (1): 76-84. 10.1097/CEJ.0b013e32830c8dca.CrossRefPubMed
13.
Benzeval M, Der G, Ellaway A, Hunt K, Sweeting H, West P, Macintyre S: Cohort profile: west of scotland twenty-07 study: health in the community. Int J Epidemiol. 2009, 38 (5): 1215-1223. 10.1093/ije/dyn213.CrossRefPubMed
14.
Brooks RG, Rabin F, De Charro F: The measurement and valuation of health status using EQ-5D:a European perspective:evidence from the EuroQol BIOMED Research Programme. Kluwer Academic Publishers. 2003
15.
16.
17.
Scheier MF, Carver CS, Bridges MW: Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol. 1994, 67 (6): 1063-1078.CrossRefPubMed
18.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes JCJM, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European-organization-for-research-and-treatment-of-cancer Qlq-C30 - a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer I. 1993, 85 (5): 365-376. 10.1093/jnci/85.5.365.CrossRef
19.
Bjordal K, Kaasa S, Ahlnerelmqvist M, Tollesson E, Bonde A: Development of a head and neck cancer-specific module for use with the Eortc core quality-of-life questionnaire (Eortc Qlq-C30). Qual Life Res. 1993, 2 (1): 72-
20.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiat Scand. 1983, 67 (6): 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed
21.
Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985, 122 (1): 51-65.PubMed
22.
Humphris G, Ozakinci G: The AFTER intervention: a structured psychological approach to reduce fears of recurrence in patients with head and neck cancer. Br J Health Psychol. 2008, 13 (Pt 2): 223-230.CrossRefPubMed
23.
Castellsague X, Bosch FX, Munoz N, Meijer CJLM, Shah KV, De Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. New Engl J Med. 2002, 346 (15): 1105-1112. 10.1056/NEJMoa011688.CrossRefPubMed
24.
Ho KF, Farnell DJJ, Routledge JA, Burns MP, Sykes AJ, Slevin NJ, Davidson SE: Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy. Eur J Cancer. 2009, 45 (11): 1992-1998. 10.1016/j.ejca.2009.04.010.CrossRefPubMed
25.
Hassan SJ, Weymuller EA: Assessment of quality of life in head and neck cancer patients. Head Neck. 1993, 15 (6): 485-496. 10.1002/hed.2880150603.CrossRefPubMed
26.
Rogers SN, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller EA: The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck. 2002, 24 (6): 521-529. 10.1002/hed.10106.CrossRefPubMed
27.
Wright EP, Kiely M, Johnston C, Smith AB, Cull A, Selby PJ: Development and evaluation of an instrument to assess social difficulties in routine oncology practice. Qual Life Res. 2005, 14 (2): 373-386. 10.1007/s11136-004-5332-4.CrossRefPubMed
28.
Carr T, Moss T, Harris D: The DAS24: a short form of the Derriford Appearance Scale DAS59 to measure individual responses to living with problems of appearance. Br J Health Psychol. 2005, 10 (Pt 2): 285-298.CrossRefPubMed
29.
Sandy J, Kilpatrick N, Persson M, Bessel A, Waylen A, Ness A, Ireland A: Why are multi-centre clinical observational studies still so difficult to run?. Br Dent J. 2011, 211 (2): 59-61. 10.1038/sj.bdj.2011.570.CrossRefPubMed
Metadata
Title
Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000
Authors
Andrew Robert Ness
Andrea Waylen
Katrina Hurley
Mona Jeffreys
Chris Penfold
Miranda Pring
Sam Leary
Christine Allmark
Stu Toms
Susan Ring
Tim J Peters
Will Hollingworth
Helen Worthington
Chris Nutting
Sheila Fisher
Simon N Rogers
Steven J Thomas
The Head and Neck 5000 Study Team
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-973

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer

Research article

Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients

Research article

Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia

Study protocol

Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a multicentre randomised controlled trial (EGeSOR)

Research article

Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals

Research article

Therapeutic effects of lentivirus-mediated shRNA targeting of cyclin D1 in human gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits